Tribute Pharmaceuticals Canada (TBUFF) Stock Price, News & Analysis

Company Overview

Tribute Pharmaceuticals Canada Inc. is a Canadian specialty pharmaceutical company engaged in the acquisition, in-licensing and marketing of prescription pharmaceutical products. Focused exclusively on the Canadian market, Tribute builds its portfolio by partnering with global innovators and delivering therapies across a variety of therapeutic areas. The company’s strategy is centered on identifying established products with strong commercial potential and leveraging its in-house expertise in regulatory affairs, reimbursement and sales to maximize their market reach.

Tribute’s product portfolio spans multiple therapeutic categories, including gastrointestinal, cardiovascular, pain management and neurology. By collaborating with original equipment manufacturers and international biotechnology firms, the company brings both branded and generic medicines to Canadian pharmacies, hospitals and clinics. Tribute supports its products with professional education programs and patient support services designed to enhance compliance and clinical outcomes.

Founded in 2012 and headquartered in Cambridge, Ontario, Tribute Pharmaceuticals is publicly traded on the TSX Venture Exchange and the U.S. OTC market under the symbol TBUFF. The company is led by Chair and Chief Executive Officer Debra Frei, alongside a management team with extensive experience in pharmaceutical commercialization. Through strategic partnerships and targeted marketing efforts, Tribute continues to expand its product offerings and strengthen its presence in Canada’s pharmaceutical industry.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 50,100 shs
• Average Volume: 71,826 shs
• Market Capitalization: $105.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TBUFF Stock Analysis - Frequently Asked Questions

How were Tribute Pharmaceuticals Canada's earnings last quarter?

Tribute Pharmaceuticals Canada Inc. (OTCMKTS:TBUFF) posted its quarterly earnings results on Monday, March, 31st. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.02) by $0.01. The business had revenue of $2.90 million for the quarter.

How do I buy shares of Tribute Pharmaceuticals Canada?

Shares of TBUFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 3/31/2014
• Today: 9/07/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:TBUFF
• CIK: N/A
• Web: www.tributepharma.ca
• Phone: +1-905-8761118
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 113,720,000
• Free Float: N/A
• Market Cap: $105.76 million
• Optionable: Not Optionable
• Beta: N/A